GB201102366D0 - Methods and reagents for the treatment of allergic disorders - Google Patents

Methods and reagents for the treatment of allergic disorders

Info

Publication number
GB201102366D0
GB201102366D0 GBGB1102366.0A GB201102366A GB201102366D0 GB 201102366 D0 GB201102366 D0 GB 201102366D0 GB 201102366 A GB201102366 A GB 201102366A GB 201102366 D0 GB201102366 D0 GB 201102366D0
Authority
GB
United Kingdom
Prior art keywords
reagents
treatment
methods
allergic disorders
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1102366.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XARAGEN PHARMA Ltd
Original Assignee
XARAGEN PHARMA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XARAGEN PHARMA Ltd filed Critical XARAGEN PHARMA Ltd
Priority to GBGB1102366.0A priority Critical patent/GB201102366D0/en
Publication of GB201102366D0 publication Critical patent/GB201102366D0/en
Priority to PCT/GB2012/050288 priority patent/WO2012107769A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
GBGB1102366.0A 2011-02-10 2011-02-10 Methods and reagents for the treatment of allergic disorders Ceased GB201102366D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1102366.0A GB201102366D0 (en) 2011-02-10 2011-02-10 Methods and reagents for the treatment of allergic disorders
PCT/GB2012/050288 WO2012107769A1 (en) 2011-02-10 2012-02-09 Treatment of allergic disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1102366.0A GB201102366D0 (en) 2011-02-10 2011-02-10 Methods and reagents for the treatment of allergic disorders

Publications (1)

Publication Number Publication Date
GB201102366D0 true GB201102366D0 (en) 2011-03-30

Family

ID=43859239

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1102366.0A Ceased GB201102366D0 (en) 2011-02-10 2011-02-10 Methods and reagents for the treatment of allergic disorders

Country Status (2)

Country Link
GB (1) GB201102366D0 (en)
WO (1) WO2012107769A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) * 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4395420A (en) * 1981-12-09 1983-07-26 Bernstein Joel E Method and composition for treating pruritis
US4603131A (en) * 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose

Also Published As

Publication number Publication date
WO2012107769A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
IL288048A (en) Methods of treating or preventing cholesterol related disorders
IL261768B (en) Devices and methods for the treatment of tissue
EP2621499A4 (en) Methods for the treatment of allergic diseases
IL226401A0 (en) Methods of treating fgf21-associated disorders
TWI560200B (en) Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
EP2552433A4 (en) Compositions and methods for the treatment of somatosensory disorders
EP2670434A4 (en) Treatment of tauopathies
ZA201304334B (en) Methods for diagnosing and treating eye-length related disorders
EP2723902A4 (en) Treatment and diagnosis of epigenetic disorders and conditions
EP2696874A4 (en) Compositions and methods for the treatment of nasal conditions
PL3581199T3 (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
IL229658A0 (en) Scyllo-inositol for the treatment of behavioral and psychiatric disorders
GB201207599D0 (en) Transistor and the method of manufacture
IL225896A0 (en) Treatment of mecp2-associated disorders
EP2675275A4 (en) Compositions and methods for the treatment of obesity and related disorders
EP2710384A4 (en) Diagnosis and treatment of copd
EP2681209A4 (en) Compounds and methods for the treatment of pain and other disorders
HK1186986A1 (en) Method for treating disorders of the skin
HK1216721A1 (en) Uses and methods for the treatment of liver diseases or conditions
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
EP2734188A4 (en) Compositions and methods for the treatment of ocular surface allergies
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
EP2777660A4 (en) Method for preventing the onset and progression of myopia
GB201020085D0 (en) Methods and reagents for the treatment of arthritic disorders

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)